ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE) The purpose of this study is to evaluate the efficacy and safety of ILT-101 (human recombinant interleukin 2 (IL-2)) in patients with moderate to severe systemic lupus erythematosus.

• Country None
• organs None
• Specialty None

Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes Human recombinant interleukin-2 (rhIL-2) is a biological signalling protein playing a key role in the regulation of the immune system. At high doses, rhIL-2 activates the immune effectors ...

• Country None
• organs None
• Specialty None

T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study T regulatory lymphocytes were shown to be partly responsible for immune tolerance to cancer cells. In that respect these cells oppose to the mounting of an efficacious immune response need...

• Country None
• organs None
• Specialty None